JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Key Points

• JPMorgan Chase raised its price target on Guardant Health to $135 with an "overweight" rating, implying roughly a 47% upside from the prior close.
• Guardant posted strong Q1 results — revenue $301.7M (~48% YoY), oncology revenue $205M and test volume +47% — and raised FY2026 revenue guidance to roughly the $1.3B range, underpinning the recent share rally.
• However, the company remains unprofitable (negative EPS and consensus expects losses for the year), so the stock's valuation hinges on sustained top-line execution and could remain volatile.

Guardant Health (NASDAQ:GH - Get Free Report) had its price objective lifted by research analysts at JPMorgan Chase & Co. from $130.00 to $135.00 in a report issued on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 47.11% from the stock's previous close.

Several other brokerages have also commented on GH. Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 20th. Canaccord Genuity Group increased their target price on Guardant Health from $125.00 to $135.00 and gave the company a "buy" rating in a research report on Friday, February 20th. Citigroup lifted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the company a "buy" rating in a research note on Friday, February 20th. Wells Fargo & Company boosted their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, February 20th. Finally, Raymond James Financial restated an "outperform" rating and set a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Guardant Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.16.

Guardant Health Trading Down 0.5%

Shares of Guardant Health stock traded down $0.50 during trading hours on Friday, reaching $91.77. The stock had a trading volume of 1,737,746 shares, compared to its average volume of 2,037,164. The stock's 50 day moving average is $88.93 and its 200 day moving average is $96.92. Guardant Health has a twelve month low of $36.36 and a twelve month high of $120.74. The firm has a market capitalization of $12.17 billion, a PE ratio of -27.68 and a beta of 1.48.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. The firm's revenue for the quarter was up 39.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.62) EPS. As a group, sell-side analysts predict that Guardant Health will post -2.87 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In other news, CFO Michael Brian Bell sold 3,000 shares of the firm's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the transaction, the chief financial officer directly owned 43,601 shares of the company's stock, valued at approximately $3,795,031.04. This trade represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the business's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the transaction, the director owned 1,193 shares in the company, valued at $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,596 shares of company stock valued at $775,767 over the last ninety days. 6.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Guardant Health

A number of large investors have recently made changes to their positions in GH. Vanguard Group Inc. lifted its position in Guardant Health by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company's stock worth $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 33.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company's stock valued at $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Guardant Health by 6.6% in the 3rd quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company's stock worth $320,378,000 after acquiring an additional 317,906 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company's stock worth $343,348,000 after acquiring an additional 435,232 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Guardant Health by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company's stock worth $328,297,000 after acquiring an additional 277,001 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Q1 revenue and growth materially beat expectations — revenue was $301.7M, up ~48% year-over-year; oncology revenue was $205M and test volume rose ~47% (≈86k oncology tests), signaling strong demand. Guardant Health Reports First Quarter 2026 Financial Results
• Positive Sentiment: Company raised FY2026 revenue guidance (roughly to the ~$1.3B range), which supports forward revenue visibility and underpins the share-price rally. Guidance Press Release
• Positive Sentiment: EPS slightly better than estimates — reported loss per share of ($0.45) vs. consensus around ($0.47), a modest beat that reduces near-term downside risk from earnings surprises. Zacks: Q1 Loss, Beats Revenue Estimates
• Neutral Sentiment: Management commentary and detail are available — investors can review the earnings slide deck and the full earnings call transcript to assess margin trajectory, guidance drivers, and commercialization cadence. Earnings Call Transcript Q1 Slide Deck
• Negative Sentiment: Company remains unprofitable on an EPS basis and consensus still expects negative full-year EPS (analysts forecast continued losses), so valuation depends on sustained top-line execution and progress toward profitability. Q1 Earnings Snapshot
• Negative Sentiment: Trading remains somewhat volatile and below average volume today versus typical averages — keep an eye on liquidity and post-earnings selling pressure if future quarters miss elevated expectations. MSN Coverage

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.